Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma

Antônio Palumbo ,Angelo Vacca,Mohamed H Zaki,Hartmut Goldschmidt,Albert Oriol,Ana Slaughter,Meletios A Dimopoulos,Michel Delforge,Jennifer Herring,Philippe Moreau,Paolo Corradini,Katja Weisel,Enrique M Ocio,Concetta Conticello,Teresa Peluso,Mathew Simcock,Markus Hansson,Michèle Cavo ,Lars Sternås ,María Jesús Blanchard

doi:10.1182/blood.v124.21.4770.4770

Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma

Antônio Palumbo , Angelo Vacca + Show 18 more

https://doi.org/10.1182/blood.v124.21.4770.4770

Copy DOI

Journal: Blood	Publication Date: Dec 6, 2014
Citations: 1

Affiliation: University of Turin, Polytechnic University of Bari, University of Bari Aldo Moro, University Hospital Heidelberg, Heidelberg University, Hospital Universitari Germans Trias i Pujol, Bristol-Myers Squibb (Switzerland), National and Kapodistrian University of Athens, Belgian Society of Medical Oncology, Belgian Hematological Society, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Tübingen, Instituto de Investigación Biomédica de Salamanca, University of Catania, Skåne University Hospital, Lund University, University of Bologna, Hospital Universitario Ramón y Cajal

#Celgene Corporation #Low-dose Dexamethasone + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.